| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PNAS..110E1490M |
| P356 | DOI | 10.1073/PNAS.1219992110 |
| P932 | PMC publication ID | 3631697 |
| P698 | PubMed publication ID | 23576735 |
| P5875 | ResearchGate publication ID | 236193293 |
| P2093 | author name string | Mathieu Lupien | |
| Tian-Li Wang | |||
| András Lánczky | |||
| Luca Magnani | |||
| Alexander Stoeck | |||
| Anne C Mirabella | |||
| Balázs Gyorffy | |||
| Xiaoyang Zhang | |||
| P2860 | cites work | Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project | Q21061203 |
| From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response | Q24313831 | ||
| Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. | Q24537640 | ||
| Differential oestrogen receptor binding is associated with clinical outcome in breast cancer | Q24595511 | ||
| Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities | Q24617969 | ||
| Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen | Q24632895 | ||
| FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription | Q24645118 | ||
| Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers | Q24651915 | ||
| FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin | Q24673476 | ||
| The KEGG resource for deciphering the genome | Q27860687 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
| A gene-expression signature as a predictor of survival in breast cancer | Q27860945 | ||
| Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome | Q28131828 | ||
| ChIP-seq accurately predicts tissue-specific activity of enhancers | Q28235102 | ||
| Control of developmental regulators by Polycomb in human embryonic stem cells | Q28235841 | ||
| Histone modifications at human enhancers reflect global cell-type-specific gene expression | Q28238467 | ||
| The gamma-secretase complex: membrane-embedded proteolytic ensemble | Q28248433 | ||
| Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1 | Q28260929 | ||
| Whole-genome analysis informs breast cancer response to aromatase inhibition | Q28269291 | ||
| Galaxy: a web-based genome analysis tool for experimentalists | Q28270252 | ||
| A chromatin landmark and transcription initiation at most promoters in human cells | Q29547180 | ||
| Mapping and analysis of chromatin state dynamics in nine human cell types | Q29547552 | ||
| Notch signalling: a simple pathway becomes complex | Q29555851 | ||
| A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression | Q29614326 | ||
| A unique chromatin signature uncovers early developmental enhancers in humans | Q29614327 | ||
| Discovery and characterization of chromatin states for systematic annotation of the human genome | Q29614411 | ||
| Genome-wide map of nucleosome acetylation and methylation in yeast | Q29614525 | ||
| GREAT improves functional interpretation of cis-regulatory regions | Q29614846 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells | Q30309688 | ||
| Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells | Q30440238 | ||
| Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells | Q30472602 | ||
| The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery | Q30850738 | ||
| Privileged scaffolds for blocking protein-protein interactions: 1,4-disubstituted naphthalene antagonists of transcription factor complex HOX-PBX/DNA. | Q31085384 | ||
| An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients | Q33519584 | ||
| A CTCF-independent role for cohesin in tissue-specific transcription | Q33812535 | ||
| The loss of estrogen and progesterone receptor gene expression in human breast cancer | Q33923695 | ||
| PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer. | Q34085622 | ||
| EpiChIP: gene-by-gene quantification of epigenetic modification levels | Q34153347 | ||
| Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance | Q34164930 | ||
| Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole | Q34173468 | ||
| Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells | Q34192940 | ||
| FOXA1 is a key determinant of estrogen receptor function and endocrine response | Q34508204 | ||
| Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial | Q44875574 | ||
| Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase | Q45309214 | ||
| The importance of gene-centring microarray data | Q46051909 | ||
| Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes | Q46370672 | ||
| Model systems: mechanisms involved in the loss of sensitivity to letrozole | Q46557591 | ||
| Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. | Q46720989 | ||
| Correlation of histologic grade with other clinicopathological parameters, intrinsic subtype, and patients' clinical outcome in Taiwanese women. | Q51390882 | ||
| Activation of the rat renin promoter by HOXD10.PBX1b.PREP1, Ets-1, and the intracellular domain of notch. | Q52054027 | ||
| Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. | Q53529945 | ||
| Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. | Q54565799 | ||
| The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy | Q69227812 | ||
| Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo | Q73270417 | ||
| Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation | Q75447880 | ||
| Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter | Q77953933 | ||
| Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00) | Q79215184 | ||
| Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. | Q34920304 | ||
| CYP2D6 and tamoxifen: DNA matters in breast cancer | Q34993830 | ||
| Epigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions | Q35145499 | ||
| AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription | Q35161945 | ||
| Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials | Q35186747 | ||
| ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer | Q35479617 | ||
| Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer | Q35558909 | ||
| Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches | Q35652417 | ||
| Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells | Q35779043 | ||
| Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch | Q35779391 | ||
| A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. | Q35837764 | ||
| Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics | Q36021732 | ||
| Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells | Q36471410 | ||
| PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas | Q36611174 | ||
| Mechanisms of endocrine resistance in breast cancer | Q36851417 | ||
| Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts | Q36916606 | ||
| Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer | Q37085602 | ||
| Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer | Q37305014 | ||
| Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor | Q37321086 | ||
| Biological determinants of endocrine resistance in breast cancer | Q37585095 | ||
| Discovery of functional noncoding elements by digital analysis of chromatin structure | Q37695799 | ||
| Epigenetic reprogramming--taking a lesson from the embryo | Q37764153 | ||
| Antiestrogens and their therapeutic applications in breast cancer and other diseases | Q37807420 | ||
| Epigenomic enhancer profiling defines a signature of colon cancer | Q39365031 | ||
| An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition | Q39561780 | ||
| Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. | Q39667297 | ||
| Inhibition of cancer cell proliferation by designed peptide amphiphiles. | Q39878873 | ||
| Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant | Q40192741 | ||
| Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model | Q40408882 | ||
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 | ||
| Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen | Q40639744 | ||
| Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells | Q42180992 | ||
| Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation | Q42526578 | ||
| Pre-B cell to macrophage transdifferentiation without significant promoter DNA methylation changes | Q42587665 | ||
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 | ||
| Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. | Q43144706 | ||
| De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model | Q43244786 | ||
| Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment | Q44102217 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | E1490-9 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer | |
| P478 | volume | 110 |
| Q26765912 | A Role for Notch Signalling in Breast Cancer and Endocrine Resistance |
| Q54118050 | A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer. |
| Q35574894 | A cluster of noncoding RNAs activates the ESR1 locus during breast cancer adaptation. |
| Q37667038 | Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer |
| Q37255088 | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications |
| Q37149776 | Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis |
| Q36817914 | ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. |
| Q35016088 | Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies |
| Q36355992 | DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation |
| Q27342622 | Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion |
| Q38218657 | Drug resistance to targeted therapies: déjà vu all over again |
| Q92683767 | Dysregulation of DNA methylation patterns may identify patients with breast cancer resistant to endocrine therapy: A predictive classifier based on differentially methylated regions |
| Q36583584 | ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors |
| Q35926106 | Embryonic Stem Cell (ES)-Specific Enhancers Specify the Expression Potential of ES Genes in Cancer |
| Q38997020 | Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations |
| Q64974925 | Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. |
| Q38163573 | Endocrine resistance in breast cancer |
| Q57472758 | Endocrine therapy-resistant breast cancer model cells are inhibited by soybean glyceollin I through Eleanor non-coding RNA |
| Q34624854 | Enhancer alterations in cancer: a source for a cell identity crisis |
| Q38826989 | Enhancer deregulation in cancer and other diseases |
| Q34022694 | Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer |
| Q46509951 | Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles. |
| Q21131237 | Exploiting tumor epigenetics to improve oncolytic virotherapy |
| Q58738574 | FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome |
| Q37379842 | FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer |
| Q38421414 | Gene expression-based prognostic and predictive tools in breast cancer |
| Q36029524 | HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance |
| Q93087327 | High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma |
| Q92451925 | High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer |
| Q37214212 | Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis |
| Q48090571 | Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients |
| Q34069945 | Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance |
| Q89623342 | Lipid Transfer Proteins and Membrane Contact Sites in Human Cancer |
| Q34979662 | Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer |
| Q38997053 | Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation |
| Q38839786 | MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. |
| Q59791901 | Moving Breast Cancer Therapy up a Notch |
| Q37728495 | Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer. |
| Q33892801 | Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. |
| Q97420338 | Notch Signaling Pathway and Endocrine Resistance in Breast Cancer |
| Q37588298 | Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer |
| Q89665043 | Nucleosome destabilization by nuclear non-coding RNAs |
| Q89548733 | Oct4-Mediated Inhibition of Lsd1 Activity Promotes the Active and Primed State of Pluripotency Enhancers |
| Q38734364 | Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. |
| Q42755954 | Overcoming Resistance to Endocrine Therapy in Breast Cancer: New Approaches to a Nagging Problem |
| Q38694214 | PBX1 attributes as a determinant of connexin 32 downregulation in Helicobacter pylori-related gastric carcinogenesis |
| Q93186271 | Pathways to Endocrine Therapy Resistance in Breast Cancer |
| Q38254072 | Poised epigenetic states and acquired drug resistance in cancer |
| Q55000405 | Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. |
| Q64060396 | SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer |
| Q36578211 | Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells |
| Q33827053 | Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors. |
| Q34667770 | Systematic nucleo-cytoplasmic trafficking of proteins following exposure of MCF7 breast cancer cells to estradiol |
| Q38637158 | TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. |
| Q89667670 | Targeting cancer stem cell pathways for cancer therapy |
| Q64081660 | Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance |
| Q99590082 | The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer Cells |
| Q34883436 | The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. |
| Q37619817 | The mitotic tensegrity guardian tau protects mammary epithelia from katanin-like1-induced aneuploidy. |
| Q36355823 | The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer |
| Q36030226 | Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer |
| Q38215923 | Toxicogenomics and cancer susceptibility: advances with next-generation sequencing. |
| Q39246718 | Tumor heterogeneity and personalized cancer medicine: are we being outnumbered? |
Search more.